EQL Pharma AB (OSTO:EQL) Total Assets: kr850.9 Mil (As of Mar. 2026)


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.15
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB Total Assets?

EQL Pharma AB OSTO:EQL -2.32% 42 Total Assets is kr850.9 Mil as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

EQL Pharma AB's Total Assets for the quarter that ended in Mar. 2026 was kr850.9 Mil.

Warning Sign:

If a company builds assets at 39.4% a year, faster than its revenue growth rate of 11.8% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, EQL Pharma AB's average Total Assets Growth Rate was 5.20% per year. During the past 3 years, the average Total Assets Growth Rate was 46.90% per year. During the past 5 years, the average Total Assets Growth Rate was 39.40% per year. During the past 10 years, the average Total Assets Growth Rate was 40.00% per year.

During the past 13 years, EQL Pharma AB's highest 3-Year average Total Assets Growth Rate was 54.60%. The lowest was 18.80%. And the median was 44.90%.

Total Assets is connected with ROA %. EQL Pharma AB's annualized ROA % for the quarter that ended in Mar. 2026 was -1.79%. Total Assets is also linked to Revenue through Asset Turnover. EQL Pharma AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.14.

EQL Pharma AB  (OSTO:EQL) Total Assets Explanation

Total Assets is connected with ROA %.

EQL Pharma AB's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-14.86/( (813.537+850.887)/ 2 )
=-14.86/832.212
=-1.79 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

EQL Pharma AB's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=120.167/( (813.537+850.887)/ 2 )
=120.167/832.212
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

EQL Pharma AB Total Assets Related Terms

EQL Pharma AB Total Assets Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Total Assets Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 237.89 285.70 373.76 808.82 850.89

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 808.82 797.28 825.18 813.54 850.89
OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

EQL Pharma AB's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (A: Mar. 2026 )+Total Liabilities (A: Mar. 2026 )
=267.056+583.831
=850.9

EQL Pharma AB's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=267.056+583.831
=850.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of kr850.9 Mil mean?
EQL Pharma AB (OSTO:EQL) has a Total Assets of kr850.9 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Total Assets too high?
EQL Pharma AB's current Total Assets is kr850.9 Mil. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Total Assets compare to ZTS and UTHR?
EQL Pharma AB's Total Assets of kr850.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Total Assets is kr850.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Total Assets of kr850.9 Mil. The current Total Assets is kr850.9 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Total Assets is kr850.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.15
Price